CPT® Code 90284

1. Indications

Immune globulin (SCIg) is indicated for use in various clinical scenarios where passive immunity is beneficial. The following conditions and situations warrant the administration of this therapeutic agent:

• Prevention of Infections SCIg is utilized to prevent or reduce the severity of certain infections in patients who are at risk due to compromised immune systems.
• Immune System Disorders It is used to treat patients with immune system problems, providing necessary antibodies to help bolster their immune response.
• Thrombocytopenia SCIg can be indicated for patients suffering from thrombocytopenia, a condition characterized by low platelet counts, which can lead to increased bleeding risks.
• Kawasaki Syndrome This therapy is also indicated in the treatment of Kawasaki syndrome, a condition that primarily affects children and can lead to inflammation of blood vessels.

2. Procedure

The procedure for administering immune globulin (SCIg) involves several key steps to ensure safe and effective delivery of the therapy. Each step is critical for achieving the desired therapeutic outcomes.

• Step 1: Patient Assessment Prior to administration, a thorough assessment of the patient’s medical history and current health status is conducted. This includes evaluating any previous reactions to immune globulin products and determining the appropriateness of SCIg therapy based on the patient's specific condition.
• Step 2: Preparation of the Product The immune globulin product is prepared according to the manufacturer's instructions. This may involve allowing the solution to reach room temperature and ensuring that it is free from particulate matter or discoloration before use.
• Step 3: Administration Technique The immune globulin is administered subcutaneously, typically in multiple sites to minimize discomfort and enhance absorption. The healthcare provider will select appropriate injection sites, often in the abdomen or thigh, and use aseptic technique to prevent infection.
• Step 4: Monitoring After administration, the patient is monitored for any immediate adverse reactions or side effects. Vital signs may be checked, and the patient is observed for signs of allergic reactions or infusion-related complications.

3. Post-Procedure

Following the administration of immune globulin (SCIg), patients may experience some mild side effects, such as local site reactions, including redness or swelling. It is important for healthcare providers to provide post-procedure care instructions, which may include advising patients to monitor for any unusual symptoms or reactions in the days following the infusion. Patients should be informed about the signs of potential adverse effects, such as fever, rash, or difficulty breathing, and instructed to seek medical attention if these occur. Additionally, follow-up appointments may be scheduled to assess the effectiveness of the treatment and to determine if further doses are necessary based on the patient's ongoing health needs.